Official Title:  A Phase 1/2 open- label, multi -center, safety and tolerability study of a  
single dose of 68Ga -PSMA -R2 in patients with biochemical relapse (BR)  
and metastatic prostate cancer (mPCa).  
NCT Number:  
Document  Date : [STUDY_ID_REMOVED] 
SAP Version 2.0:  29 June 2020 
8/11/[ADDRESS_1003055] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 1/49Statist ical Anal ysis Plan 
STATISTICAL ANALYSIS PLA N 
A206O-A01-[ADDRESS_1003056] ications 
PROTOCOL A206D -A01-001 
Page 1 of 48 
A PHASE 1/11 OPE N-LABEL , MULT I-CENTE R, SAFETY AND 
TOLERABILITY STUDY OF A SI NGLE DOSE OF 68GA-PSMA-R2 IN 
PATIENTS WITH BIOCHEMICAL RELAPSE (BR) AND METASTATIC 
PROSTATE CANCER (MP CA) 
A UTH OR:      
 
V ERSION NUMBER AND DATE: V2.0, 29illN2020 
Document: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date : 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003057] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 2/49Statist ical Anal ysis Plan Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 2 of 48 
STATISTI CAL ANALYSIS PLAN SIGNAT URE PAGE 
Statistical Analysis Plan V2.0 (Dated 29JUN2020) for Protocol A206D -AOI-OOI. 
Name [CONTACT_310853] :  DDMMMYYYY 
Position:  
Compa ny:  
Upon review of this document, the undersigned approves this version of the Statistical Analysis Plan , authorizing 
that the content is acceptable for the report ing of this study. 
Name [CONTACT_310854]:  [CONTACT_734076]:  
Compa ny:  
Approved By:  [CONTACT_734076]:  
Compa ny:  
Approved By:  [CONTACT_734076]:  
Compa ny:  
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date: 2gJLJN2020 
Reference : CS_Wl_BS005 
 
 

8/11/[ADDRESS_1003058] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 3/49 
Statistical Analysis Plan 
Approved By: 
[CONTACT_70821]: 
Company : 
Approve d By: 
[CONTACT_734077]: 
Compa ny: 
Approved By: 
[CONTACT_70821]:  
 
AAA 
 
 
AAA 
Company: AAA Advanced Accelerator Applications 
PROTOCOL A206D -A01--001 
Page 3 of48 
 
 
 DDMMMYYYY 
DDMMMYYYY 
[).. '1 -JUM -t.OW 
Document 
Author. K:\AAA\Ga-PSMA-R2\VYA27826\ Biostatistics\Documentation\SAP\v2.0\Ga-PSMA-R2-SAP _v2.0 
 Version Number: 2.0 
 
Template No.: CS_ TP _BS016 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS WI_BS005 
 
 

8/11/[ADDRESS_1003059] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 4/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 4 of 48 
STATISTI CAL ANALYSIS PLAN REVIEWED BY 
[CONTACT_734078]: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003060] ive Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003061] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 5/49Statist ical Anal ysis Plan 
MO DIFICATION HISTORY 
Unique Date of the A uthor 
Identifier Document 
for this Version 
Version 
1.[ADDRESS_1003062] ion I 5.2 -details of data 
presentat ions updated. 
Document: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003063] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 6/49Statist ical Analys is Plan 
TABLE OF CONTE TS Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 6 of 48 
A206D-A01-001 ........... ....... ....................... ......... ........... ................ .................. ........................... ....................... ...... l 
A Phase 1/11 open-label , multi- center, safety and tolerabilit y study of a single close of 68Ga-PSMA -R2 in 
patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa) ............ ............ ......................... [ADDRESS_1003064] ion ................................................................ ........................... ......... ............................................. 13 
2. Study Objectives ............................................................................................................... ....................... .... 13 
2.1. Primary Objective ........................................................................................................... ....................... .... 13 
2.2. Secondary Objectives .......................................................... ........................................... ....................... .... 13 
3. Study Design .............. ........................................................................................................ .................... ....... 13 
3.1. General Description ............................................................. ......................... ............................................. 13 
3.2. Schedule of Events ....................................................................................... .......................................... .... 14 
4. Planned Analyses .............. ........................... ............................... ................ .......... ................. ...................... 14 
4.1. PK Analysis ..................... ........................... ........................... ........... ......... ......•................... ....................... 14 
4.2. Biodistribution , Dosimetry and Imaging Analysis .................•... .......................•.... ................ ......•............... 14 
4.3. Final Analysis ............................................................ .................................... ......................... ................ .... 15 
S. Analysis Sets .............. ....................... ........................................................................................ ................. ... 15 
5.1. All Patients Enrolled Set [ENR] ............................... ........................... ........................... ....... .................... ... 15 
5.2. Full Analysis Set [FAS ] .......................................................... ........................................... ....................... .... 15 
5.3. Per Protocol Set [PPS] .......................................................... .................................................................. .... 15 
6. General Consideration s ......................................................... ........................................... ....................... .... 15 
6.1. Popu lation Summari zation .................................................. ......................... ............................................. 15 
Document: K:\AM\ Ga-PSMA-R2 \VYA27826 \ Biostat istics\Docu mentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003065] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 7/49Statistical Analysis Plan Advanced A ccelerator Appl ications 
PROTO COL A 206D-A01-[ADDRESS_1003066] s ....... ........................... ........................... ........... ................ ........................... ........... ............ 17 
6.7. Common Calculations ........................ ........... ................ ........... ................ ........................... ....................... 17 
6.8. Softw a re Ve rs ion ............... ................ ........... ................ ........... ................ ........................... ....................... 17 
7. Sta tistic.al Consideration s ................................ ............ ........... ................ ......... .................. ........................... 17 
7.1. Adjustments for Covari ates and Factors to be Included in Analyses ................................... ................... .... 17 
7.2. Mu lticenter Studies ....................... ........................ ............. .............. ........................... .......................... .... 17 
7.3. Missing dat a ............................... ........................... ........................... ........................... .......................... .... 18 
7.4. Mu ltiple Comp arisons/ Multiplicity ............ ........... ........................... ........................... .......................... .... [ADDRESS_1003067].ics ................. ................ ........................... ....................... 19 
11. Medical and Prosta te Cancer History ......... ................ ........... ................ ........................... ....................... 19 
11.1. Medical History ........... ................... ........ ................... ........... ................ .......•............... ...........•............... 20 
11.2. Prostat e Ca ncer History ................. .................................. ............. ............ ...................... ............ ........... 20 
11.2.1. Derivations ......... ....................... ........................... ........................ ........................... .......................... .... 21 
12. Cancer therapie s, Medicatio ns, Proc edur es and Radioth erapy ................................... ....................... .... 21 
12.1. Prior a nd C oncomit ant Cancer Thera pi[INVESTIGATOR_014] ........... .............. ............. ........................... .......................... .... 21 
12.2. Prior a nd C oncomit ant non-cancer me dications ......................................................... ....................... .... 21 
Docum ent: K:\AM\ Ga-PSM A-R2\VY A278 26\ B iostatistics \Documen tation\SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Numbe r: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr20 18 Version Date: 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003068] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 8/49Statistical Analysis Plan Advanced A ccelerator Appl ications 
PROTO COL A 206D-A01-001 
Page 8 of 48 
12.3. Prior and Concomitant Procedur es ......... ........... ........................... ........................... .......................... .... 22 
12.4. Prior and Concomitant Radiotherap y ................. .............. ............. .................................. ................... .... 22 
13. S tudy Me dication Exposure ......... ........................... ........... ................ .................................................. .... 22 
14. Safety Outcom es ............................... ........................... ........... ................ ........................... ........... ............ 23 
14.1. Adverse Events .............................. ........................... ........... ................ ........................... ........... ............ 23 
14.1.1. All TEAEs ................. ....................... ........... ................ ........... ................ ........................... ....................... 24 
[IP_ADDRESS] . Severity ........... ........... ................ ........ ................... ........... ................ .......•............... ...........•............... 24 
[IP_ADDRESS]. Relationsh ip to Study Med ication ......... ........................... ..................... ...................... ....................... 24 
[IP_ADDRESS]. Relationsh ip to Study Procedure ........................... ...................................................... ................... .... 24 
14.1.2. TEA Es Leading to Discontinuation of Study ..................... ................................................ ................... .... 24 
14.1.3. Serious Advers e Events ........... ........................... ........................... ..................................................... .... 24 
14.1.4. Adverse Events Leading to Death ............ ........... ........................... ..................................... ................ .... 25 
14.2. Laboratory Evaluations .............. ........................... ........... ................ ............................... ................... .... 25 
14.2.1. Laboratory Reference Ranges ............................... ........................... ............................... ................... .... 25 
14.2.2. Severity Grading for Laboratory Data ....................... ........................... ........................... ........... ............ 26 
14.3. ECG Evaluations ............................. ........... ................ ........... ................ ........................... ........... ............ 26 
14.3.1. ECG Mark edly Abnormal Criteria .............. ................ ........... ................ ........................... ....................... 26 
14.4. Vital Signs ........... ........... ................ ........... ................ ........... ................ ........................... ....................... 27 
14.5. ECOG ................... ........................... ....................... ........... ................ ......... ...................... ................... .... 27 
15. Biodistribution, Dosimetry and Imag ing of 68Ga-PSMA-R2 ................ .................................. ................... .... 27 
15.1. Analyses of Biodistribution and Dosimetry ...................... ........................................... ....................... .... 28 
15.2. Analyses of Imaging ................ .............................. ........... ................ .................................................. .... 28 
15.2.1. Laboratory Optimal thresho ld ............................... ........................... ............................... ................... .... 28 
Docum ent: K:\AM\ Ga-PSM A-R2\VY A278 26\ B iostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Numbe r: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003069] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSit … 9/49Statistical Analysis Plan Advanced A ccelerator Appl ications 
PROTO COL A 206D-A01-001 
Page 9 of 48 
15.2.2. L esions dete cted by [CONTACT_460987]/or conv entional scan, by [CONTACT_734079] ....................................... ............................ [ADDRESS_1003070]/M RI and /or bone scan ............. ........................... ........................... ................... .... 29 
15.2 .4. Calculation of patient level agreement of 68Ga-PSMA ·R2 PET imaging with conv ention al imaging in 
prostate can cer pa tients ............................... ........................... ........... ................ ............ ............... ........... ............ 29 
APPEN DIX I. Pr ogramming Conventions for Output s ................ ................ ............................ ...................... 31 
Outpu t File Naming Conv entions .................. ........... ................ ........... ................ ........................... ....................... 31 
Paper Size, Orientation and M argins ............. ........................... ........... ................ ........................... ............ ........... 31 
Fonts ..•.... •...••..••••...•••.•..•.... •...••..•••••..•••.•..•....•...••..•.. •...•••.•..• ....•...••• .•..•...•••.•..• ....•...• ••....•...•••.•..• ....•.....•....• ...•••••..• 31 
Header Inform ation ••.•..•.... •...••..•..•...•••.•..•.... •...•••.••.•...•••.•..• ....•...•••.••.•...•••.• ..•....•...•••....•...••••• ..•....•.••..•....•...•••• •..• 32 
Table and Listing Outpu t Conventions .........•............•....... .....•..................... ........................... ...•...................... .... 32 
Figure Outpu t Conv entions ............. .................................. ........................... ........................... .......................... .... 34 
Footnote Infor mation .................•............. ...•............•....... .....•..................... ........................... ...•............•......... .... 34 
Dates & Times .................... ............. .......... ...•.................... .............. ............. ........................... ...•...................... .... 35 
Spelling Format •••...•••.•..•.... •...••..•..•...•••.•..•....•...••..•.. •...•••.•..•....•...••• ....•...•••.•..• ....•...•••....•...•••••..• ....•...•••....• ...•••••..• 35 
Prese ntation of Popul ation G roups ............... ........................... ........................... ............ ............... ........... ............ 35 
Prese ntation of Visits ............. ....................... ........... ................ ........... ................ ........................... ....................... 35 
Listin gs •...•... ••..••••...•••. •..••...•... •••.•••••..•••.•..••... •...•••• •..•...•••.•..••... •...•••.... •...•••.•..••... •...••••...•...•••.•..•• ...•...•••....•. ..•••.•..• 36 
APPEN DIX 2. Partial Date Con vention s ............................ ............................ .......................... ............. .......... 37 
Algorithm for Prostate Canc er Hi story .......... ...................................... ......... ............ ...................... ............ ........... 37 
Algorithm for Prior/ Activ e Procedures, Radi otherapi[INVESTIGATOR_014] , Cancer The rapi[INVESTIGATOR_13265] M e dications ....... ................... .... 37 
Algorithm for Treatment Emergent of Adve rse Eve nts ......... .......... ................. ........................... ....................... .... 38 
Algorithm for Prior/ Conco m itant M e dicati o ns ................ ............. .............. ........................... .......................... .... 40 
APPENDIX 3. L aborat ory Assess ments ...................... ............................ ........................... ......................... .... 41 
Docum ent: K:\AM\ Ga-PSM A-R2\VY A278 26\ B iostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Numbe r: 2.0 
 
Version Date: 29JUN2020 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003071] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 10/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 10 of 48 
APPENDIX 4. Vital Signs measurements ....................... ......... ............... ............ ............... .......... ................ .... 45 
APPENDI X 5. Dosimetry m easurements ...................................................................................... ................ ... 47 
Document: K:\AM \Ga-PSMA-R2 \VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S016 Revision 5 
Effective Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003072] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 11/49Statist ical Analys is Plan 
LIST OF ABBREVIATIO NS 
AE Adverse Event 
ALT Alanine aminotransferase 
ALP Alka line Ph osphatase 
AST Aspartat e aminotransferase 
BLQ Below the Low er Limi t of Quantification 
BUN Blood Urea Nitrogen 
cs Clinically Significant 
CT Computed Tomograp hy 
DBP Diastolic Blood Pressure 
ECG Electrocardiogram 
ECOG Eastern Cooperati ve Oncology Group 
eCRF Electron ic Case Report Form 
EG Enterprise Guide 
eGFR Estimated Glomerular Filtrat ion Rate 
ENR All Patient s Enroll ed 
FAS Full Analysis Set 
68Ga Gallium radioisotope [ADDRESS_1003073] ications 
PROTOCOL A206D-A0 1-001 
Page 11 of 48 
MedDRA Medical Dictionary for Regulatory Activiti es 
mPCa Meta static Stage Prostate Cancer 
MRI Magnetic Resonance Imaging 
NCS Not Clinically Significant 
ODS Output Delivery System 
PCa Prostate Cancer 
PCa-BR Biochemical Recurre nce Prostate Cancer 
PET Positron Emission Tomography 
PK Pharmacokinetic(s) 
PPS Per Protocol Set 
PR PR interval of the electrocar diogram; time durat ion between the P and R 
waves 
PSA Prostate spec ific antigen 
Document: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Version Date : 29JUN2020 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003074] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 12/49Advanced Acce lerator Applications 
PROTOCOL A206D-A0 1-[ADDRESS_1003075] an 
PSMA Prostate Specific Membrane Antigen 
PT Preferred Term 
QRS QRS interval of the electrocardiogram; duration of the QRS complex 
QT QT interva l of ECG , duratio n between the Q and T waves 
OTcB QT interva l of ECG corrected for heart rate using Bazett's formula 
QTcF QT interva l of ECG corrected for heart rate using Fridericia's formula 
QI First Quarti le 
[ADDRESS_1003076] Deviation 
soc System Organ Class 
TEAE Treatment Emergent Adverse Event 
ULQ Upper Limit of Quantification 
WBC White blood cell 
WHO- DD Who Drug Dictionary 
Docu ment: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics \Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Version Date: 29JUN2020 
Template No.: CS_TP _8S016 Revision [ADDRESS_1003077] ive Date : 01Apr2018 Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003078] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 13/49Statistical Analys is Plan 
1. INTROD UCTION Advanced Accelerator Applications 
PROTOCOL A206D-A0 1-001 
Page 13 of 48 
This document descr ibes the rules and convent ions to be used in the presen tation and a nal ysis of safety data, for 
Protocol A206 D-A0I-00I. It describes the data to be summa rized and anal yzed, including spec ifics of the 
statistical analyses to be performed. 
This statistical analysis plan (SA P) is based on protocol version 2.2, dated 22 Februar y 2018. 
2. STUDY OBJ ECTIVES 
2.1. PRIM ARY OBJECTIVE 
The primary objective is to assess safety and tolerability of a single adm inistration of3 mega Becque rel (MBq)/kg, 
but not less than [ADDRESS_1003079] ives are: 
• T o assess the phar macokinetics (PK) of 68Ga-PSMA-R2. 
• T o assess biod istribution and dosi metry of 68Ga-PSMA-R 2. 
• T o establis h the optimal im aging method for determi ning l ocat ion and burden of positiv e lesio ns on 68Ga-
PS MA- R2 positron emission tomography (PET ) imag ing in patients in comparison with lesions identified 
with convent ional imaging scans (computed tomograp hy (en/ma gnetic resona nce imaging ( MRI ) and 
bone scan), and to calculate the agreement of 68Ga-PS MA-R2 PET with convent ional 
anatomical/functional imaging on a per patie nt basis. 
3. STUDY D ESIGN 
3.1. GENERAL DESCRIPTIO N 
This is an open label, multi -center, sing le dose, Phase 1/11 stud y to eval uate the safety a nd tolerabi lity of 3 
MBq / Kg, but not less than [ADDRESS_1003080] of 2 parts. 
• During the first part (Phase f), approx imately [ADDRESS_1003081] (IP) and will remain at the site for approxi mately [ADDRESS_1003082] -administration in 
order to assess the PK, biodistribution vs. time, and dosimetry for critical organs. Patien ts will receive a 
sin!de dose of3 MB9 /k2, (> 150 and< 250 MBg ), of68Ga-PSMA -R2 intrave nously. Serial blood and 
Docu ment: K:\AM \Ga-PSMA-R2 \VYA27826 \ Biostatistics\Documentation\SA P\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003083] ive Date : 01Apr2018 Version Date: 29JUN2020 
Reference: CS_Wl_BS005 
 
 

8/11/[ADDRESS_1003084] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 14/49Statistical Analys is Plan Advanced Accelerator Applications 
PROTOCOL A206D-A0 1-001 
Page 14 of 48 
urine samples will be collected for PK character ization and dosimetr y and who le body PET/CT will be 
acqu ired at selected time points (0-4 hours) to determine orga n and tumor absorbed doses. Safety 
assessments will be conducted after IP adm inistration on Day I, and during follow -up on Days 7 and 28. 
• In the secon d part of the study (Phase 11), two groups of approximately I 2 patien ts will be enro lled 
(patients with PCa in biochemical recurrence (PCa-BR), and patients with prostate cancer in the 
metastat ic stage (mPCa) ). Enrollment will be capped at I 2 patients in each group to ensure an even 
distribution of patien t conditions. If preliminary data analy sis from the Phase I part of the study prov ides 
suffic ient dosimetry data, all patie nts will undergo whole body PET/CT imaging optimized for time (up 
to 2 timepoi nts) accord ing to the data analysis from the Phase I component of the study. 
This study is comprised of 4 clin ical visits and will be conducted in 3 study periods includ ing: Screening , 
admin istration/ imaging, and safety follow-up period (final/early termi nation). 
3.2. SCHEDULE OF EVENTS 
Schedule of events can be found in Section "STUDY PROCEDURES AND ASSESSl'vlEN TS" of the protoco l. 
4. PLAN ED ANALY SES 
The following analysis will be performed for this study: 
• P hase I Analy sis assess ing PK, Biodistribution, Dosimetry and Imaging 
• Fina l Analy sis (com bining Phase I and Phase II data) 
This document will provide details for Phase I Biodi stribut ion, Dosimetry and Imaging Analysis and Fina l 
Analysis. All planned analyses identified in this SAP will be performed by  [CONTACT_734080]. 
4.1. PK ANALYSIS 
Phase I PK Analysis will be described in a separate SAP written by [CONTACT_36532] s pecialist from a third-party clinical 
pharmacokinetics vendo r. 
Derivat ion of the PK para meters and the PK summary tables , listings and figures, will be the respo nsibility of 
th ird- party clinical phar macokinetic s vendor. 
4.2. BIODISTRIBUTION , DOSIMETRY AND IMAGING ANALYSIS 
The biod istributio n, dosime try and imaging analysis will be split in two: 
• The analysis using data from the principal scientist from a third -party radiat ion dosimetry vendor will be 
performed only for Phase I. 
• T he analysis using data from a third-party medical imaging vendor will be perfo rmed for both Phase I and 
Docu ment: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostatistics\Documentation\SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003085] ive Date : 01Apr2018 Version Date: 29JUN202 0 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003086] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 15/49Statist ical Analys is Plan 
Phase II. Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 15 of 48 
Summary tables, listings and figures needed for the bi odistribut ion, dosimetry and imaging are desc ribed in 
section 15. 
4.3. FINAL ANALYSIS 
The final analysis will be conducted at the end of the study and wi ll include the analyses of safety endpo ints. This 
analys is will be based on the full analysis set (FAS) and may be repeated o n the per protocol set (PPS ). 
5. ANALYSIS SETS 
Agreement and author ization of patients included/ excluded from each analys is set will be conducted prior to the 
final databa se lock. PK analysis set will be descr ibed in the SAP written by a third party clinical pharmacokine tics 
vendor. 
5.1. ALL PATIENTS ENROLLED SET [ENR] 
The all patients enrolled (ENR) set will contain all patients who provide inform ed consent for this study. 
5.2. FULL ANALYSIS SET [FAS) 
The full analys is set (FAS ) will contain all patients who receive at least one dose of study medi cation. The safety 
set in t his case is identical to the full analysis set and so will not be defined as a separate set. 
5 .3. PER PROTOCOL SET [PPS] 
The per-protocol set (PPS) will conta in all patients in the FAS who complete the study accord ing to the protocol 
with no critical or major protocol deviations. The decisions regarding critical and major protocol deviat ions, and 
the definition of the analysis population, will be finalized prior to databa se lock. 
6. GENERAL CONSIDERATIONS 
6.1. POPULATION SUMMARIZATION 
In general, data will be presented by [CONTACT_734081]. 
• T he following populations will be used in the analyses: 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003087] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 16/49Statist ical Anal ysis Plan 
o PCa-BR 
o mP Ca Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 16 of 48 
• T he PCa-BR popu lation group will also be presented separately for Phase I and Phase II patients. 
6.2. REFERENCE START DATE AND STUDY DAY 
Study Day will be calculate d from the reference start date and will be used to show start/ stop day of assess ments 
and events. 
Reference start date is defined as the day of the first and single administration of study medi cation, (Day I is the 
day of the first and single dose of study medication). 
If the date of the event is on or after the reference date, then: 
• Study Day = ( date of event -reference date) + I . 
If the date of the event is prior to the reference date, then: 
• Study Day = (date of event -reference date). 
In the situation where the event date is partial or missin g, Study Day, and any correspon ding duration s will appear 
missing in the listings. 
6.3. BASELI NE 
Unless otherwise specified, baseli ne is defined as the last non-miss ing measurement taken prior to reference start 
date (including unscheduled assessments). In the case where the last non-missing measuremen t and the reference 
start date and time coincide, that measurement will be considered pre-baseline, but Adverse Events (AEs) and 
medicat ions commencing on the reference start date will be considered post-baseline. 
[ADDRESS_1003088]/worst case 
value where requ ired (e.g. shift tables). 
Treatment Early termination data will not be included in by-visit summar ies. 
In the case of a retest (same visit number assigne d), the earliest available measurement for that visit wi ll be used 
for by-visit summaries. 
Listings will include scheduled, unschedu led, retest and early discontinuation data. 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003089] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 17/49Statist ical Anal ysis Plan 
6.5. WINDOWING CONVE NTIONS 
No visit window ing will be performed for this study. 
[ADDRESS_1003090] S 
There will be no formal statistical testing of data. 
6.7. COMMO N CALCULATIO NS 
For quantitative measurement s, change from basel ine will be calculated as: 
• T est Value at Visit X - Baseline Value Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 17 of 48 
For quantitative measurement s, percentage of change from baseline will be calculated as: 
(Test Value at Visit X - Baseline Value ) 
Baseline Value X lOO 
6.8. SOFTWARE VERSION 
All analy ses wi ll be conducted using SAS version 9.[ADDRESS_1003091] ical testing for safety data, and no covar iate adjustment. 
7.2. MULTICE NTER STUDIES 
The study will be conducted at approx imately 4 sites in the US. All data will be pooled for summaries of safety 
with no summaries presented by [CONTACT_384]. 
Document: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003092] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 18/49Statist ical Analys is Plan 
7.3. MISSI NG DATA 
Miss ing safety data will not be imputed. Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 18 of 48 
Miss ing severity and relatedness of AEs will be handled as described in sections 14. 1.1.1 and [IP_ADDRESS] of this 
analys is plan. 
7.4. MULTIPLE COMPARISONS/ MULTIPLICIT Y 
Not appl icable. 
7.5. EXAMI NATION OF SUBGROUPS 
No subgro up analyses will be performed for this study. 
8. OUTPUT P RESENTATIONS 
APPENDIX I shows conventions for presentation of data in outputs. 
The templates prov ided with this SAP describe the presentations for this study and therefore the format and 
content of the summa ry tables, figures and listings to be provided by  [CONTACT_42075]. 
9. DISPOS ITION AND WITHDRAWALS 
All patients who provide informed consent will be accounted for in this study. 
The counts of the analysis sets will be presented : 
• All Patients Enrolled Set (EN R) 
• Full Analysis Set (FAS) 
• Per Protocol Set (PPS) 
The following patient disposition and withdrawals will be presented for the ENR set: 
• Screened 
• Screen failures 
• Phase I 
• Phase II 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0 \Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS_Wl_BS005 
 
 

8/11/[ADDRESS_1003093] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 19/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 19 of 48 
• Number of patients receivi ng study medicat ion 
• Completed study imaging assess ment s (assessed at Day 1) 
• Di scontinue d from study, reason for premature discont inuation from study 
Duration of follow-up will be presented for the ENR set. Duration of follow-up (day) is defined as date of 
completio n/discontinuati on -date of first admini stration + I. 
Critical and major protocol deviation s (as defined in sectio n 5.3) will be presented for the ENR set. 
10. DEMOGRAP HIC A D OTH ER BASELINE CHARACTE RISTICS 
Demographic data and other baseline characteristics will be presented for the FAS and PPS. 
No statistical testing will be carried out for demograph ic or other basel ine character istics. 
The following demographic characteristics will be reported: 
• Age (years) 
• R ace (Amer ican Indian or Alas ka Native, Asian, Black or African American, Native Hawaiian or 
Other Pacific Islanders, White, Other) 
• Ethn icity (Hispan ic or Latino, Not Hispan ic or Latino , Not Reported, Unknown) 
• Weight (kg) 
• Height (cm) 
The following base line character istics will be reported: 
• ECOG perfonnanc e status at baseline (0, 2:1) 
• PSA test (ng/m L) 
11. MEDICAL AND PRO STATE CA CER HISTORY 
Medical and prostate cancer history informat ion will be prese nted for the FAS and PPS and w i ll be coded using 
MedDRA versio n 21.0 or higher. 
All reported med ical and prostate cancer history will be listed. 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003094] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 20/49Statist ical Anal ysis Plan Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 20 of 48 
11.1. MEDICAL HISTORY 
Medic al history will be presented by [CONTACT_1196] (SOC) and (Preferred Term (PT). 
They will be sorte d by [CONTACT_734082], based on total count. 
See APPENDIX 2 for hand ling of partial dates for medical history. 
11.2. PROSTATE CANCER HISTOR Y 
The following prostate cancer history information, as reported in the eCRF, will be summarized: 
• T i me since first prostate cancer diagnos is (month s) 
• T i me since first metastasi s (months) 
• T i me since disease progression (months ) 
• Number of PSMA posit ive patients 
• Number of patients by [CONTACT_734083] (IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown ) 
• Number of patients by [CONTACT_734084] (IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) 
• Number of patients by [CONTACT_734085] (surgery , pharmacological, not applicable) 
• Number of patient s by [CONTACT_734086]: 
o Primary Gleason score=3 and Secondary Gleason scor=3 
o Primary Gleason score=3 and Seconda ry Glea son scor=4 
o Primary Gleason score=4 and Seconda ry Gleason scor=3 
o Primary Gleason score=4 and Secondary Glea son score =4 
o Primary Gleason score=4 and Secondary Glea son score =S 
o Primary Gleason score=S and Secondary Glea son score =4 
o Primary Gleason score=S and Secondary Glea son score =S 
Number of patients by [CONTACT_734087] >=6 (6, 7, 8, 9, 10) 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003095] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 21/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 21 of 48 
11.2.1. DERIVAT IONS 
• T i me since first prostate cancer diagnosis (months)= (date of scree ning -date of first prostate cancer 
diagnosis+ I)/ 30.4375 
• T i me since first metastasis (month s) = (date of screen ing -date of first metastasis+ I)/ 30.4375 
• T i me since disease progression (months ) = (date of scree ning -date of disease progression+ 1)/ 
30.4375 
See APPENDIX 2 for hand ling of partial dates for prostate cancer history. 
12. CA CER THERAPI[INVESTIGATOR_5165] , MEDICATIO NS, PRO CEDURES AND 
RADIOTHERAPY 
12.1. PRIOR AND CONCOMITA NT CANCER THERAPI[INVESTIGATOR_734069], as reported in the "Prior and Concomitant Canc er Therapy/M:edications" 
eCR F page, will be presented for the FAS and PPS using W HO -DD Preferred Name s. 
• Prior cance r therapi[INVESTIGATOR_734070]. 
• Concomitant cancer therapi[INVESTIGATOR_734071]: 
o started prior to, on or after the first and single dose of study medication , 
AND 
O ended on or after the date of first and single dose of study medication or were ongoing at the end of 
the study. 
Number of patients with at least one Line of therapy (Neoadjuv ant, Adjuvan t, Therapeutic for Metastati c Disease, 
Unknown), number of patients with at least one Therapy type (Chemo therapy, Hormonal, Biological, 
Immunotherapy , Other), number of patien ts with at least one Treatment intent (Curative, Palliative, Diagnostic , 
Salvage, Other ) will be presented as well as the medication and the best response of the latest therapy the patient 
received (Complete response, partial response , stable disease, progressive disease, not evaluable ). 
12.2. PRIOR AND CONCOMITANT NON-CANCER MEDICATIONS 
Medications will be presented for the FAS and PPS and coded using WHO Drug Dictionary version MAR2018 or 
higher if available at the time of the Database Lock. The medications will be summarized by [CONTACT_120055] -DD Preferred 
Names, sorted by [CONTACT_734088]. 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S016 Revision [ADDRESS_1003096] ive Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_Wl_BS005 
 
 

8/11/[ADDRESS_1003097] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 22/49Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-[ADDRESS_1003098] case; i.e. concomita nt. 
• Prior medications are those whic h started prior to the day of first and single dose of study medication . 
• Concomitant medications are those which: 
o starte d prior to, on or after the first and single dose of study medication, 
AND 
O ended on or after the date of first and single dose of study medi cation or were ongoing at the end of 
the study. 
All prior and concomita nt prohibited/restr icted medicat ions outlined in protocol section 5.6, as determined by [CONTACT_734089] , will be listed. 
12.3. PRIOR AND CONCOMITA NT PROCEDURE S 
Prior and Concom itant Proc edures (proce dure, surgery or no n-drug therapy) will be presented by [CONTACT_3592]. 
They will be sorted by [CONTACT_734090]. 
See APPENDIX 2 for hand ling of partial dates for prior and concomi tant procedures. In the case where it will not be 
possible to define a procedure as previous or active/concomitant. 
• Prior procedures are defined as those which started prior to the first and single dose of study medication. 
• Concomitant procedures are defined as those which: 
12.4. o started prior to the first and single dose of study medicatio n and are ongoi ng or active at the 
date of the first and single dose of study medic ation 
OR 
o started on or after the first and single dose of study medicat ion. 
PRIOR AND CONCOMITA NT RADIOTHERAP Y 
Prior and conco mitant radiotherapy, using radiation type as reported in the eCRF, will be presented by [CONTACT_734091] n type 
and treatment intent. The total dose received (Gray) will also be summarize d. 
See APPEND IX 2 for hand ling of partial dates for prior and concomitant radiotherapi[INVESTIGATOR_014]. In the case where it will not 
be poss ible to define a radiot herapy as prev ious or active/co ncom itant. 
• Prior radiotherapi[INVESTIGATOR_734072]. 
• Concomitant radiotherap ies are defined as those which: 
o started prior to the first and single dose of study medication and are ongoing or active at the 
date of the first and single dose of study medic ation 
OR 
o started on or after the first and single dose of study medi cation. 
13. STUDY MED ICATION EXPOSURE 
The following exposure information, as reported in the "68Ga -PSMA -R2 Injection" page of the eCRF, will be 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003099] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 23/49Statistical Analys is Plan 
summarized for the FAS and PPS: 
• pH 
• Radiochemical Purity(%) 
• P re-inject ion total dose in syringe (MBq ) 
• P ost-injection residual dose in syringe (MBq) 
• Total dose injected (MBq) 
• P re-injec tion volume of soluti on (mL) 
• P ost-inject ion volu me of solution (mL) 
• Volume of solution admin istrated (mL) 
• Gamma counter calibration factor Advanced Accelerator Applications 
PROTOCOL A206D-A0 1-001 
Page 23 of 48 
• Appeara nce (Clear and Colourless/ Not Clear and Colourles s) 
• Number of patient s with injection interrupted 
• Reason for injection interruption 
14. SAFETY OUTCOMES 
All outp uts for safety outcomes will be based on the FAS. Safety will be assessed as the primary object ive in this 
study. 
The primary endpo ints are defined as: 
• Adverse events and serious adverse events (SAEs) 
• Abso lute changes and changes from base line in clinical laboratory parame ters, vital signs and 
electrocard iogram (ECG ) 
14.1. ADVERSE EVEN TS 
Adverse Events will be coded using the Med DRA central coding dictionary, Version 21.0 or higher. 
They will be sorted by [CONTACT_734092], based on total count. 
Treatment emer gent adverse events (TEAEs) are define d as AEs that starte d or worse ned in severi ty on or after the 
first and single dose of study medication and until the last actual follow up visit. 
Docu ment: K:\AM \Ga-PSMA-R2 \VYA27826 \ Biostatistics\Documentation\SAP \v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003100] ive Date : 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003101] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 24/49Statist ical Analys is Plan Advanced Acce lerator Applications 
PROTOCOL A206D-A0 1-[ADDRESS_1003102] case; i.e. treatment emergent. 
An overall summary of number of patients within each of the catego ries descri bed in the s ub-sections below, will 
be provided as specified in the templates. 
Listings will include TEAEs and Non-TEAEs. 
14.1 .1. ALL TEAE s 
Incidence ofTEAEs, and number of events, will be presented by [CONTACT_734093]. 
[IP_ADDRESS]. Seve rity 
Severity is classed as mild, moderate, severe, life threatening/ disabling or death . TEAEs starting after the first dose 
of study medicat ion with a missing severity will be classified as severe. If a patien t reports a TEAE more than 
once within that SOC/ PT , the AE with the worst -case severity will be used in the correspond ing sever ity 
sun1maries. 
[IP_ADDRESS]. Relat ionship to Study Medica tion 
A related TEAE is defined as a TEAE with a relat ionship to study medication as "Reasonable possibility" 
according to the invest igator. TEAE s with a missing relationship to study medication will be regarded as related to 
study medication. If a patient reports the same AE more than once with in that SOC/ PT, the AE with the worst -
case relationship to study medication will be used in the corresponding relationship summaries. 
14.1. 1.3. Relat ionship to Study Procedure 
A related TEAE is defined as a TEAE with a r elationship to study proc edure as "Reasonable poss ibility" accord ing 
to the invest igator. TEAEs with a missing relat ionship to study procedure will be regarded as related to study 
procedure. If a patient reports the same AE more than on ce within that SOC/ PT, the AE with the worst -case 
relations hip to study procedure will be used in the corresponding relationship summarie s. 
14.1.2. TEAEs LEADING TO D ISCONTIN UATION OF STUDY 
TEAE s leading to study discontin uation will be identified by [CONTACT_10540] "Caus ed Study Discontinuation" category 
on the AE page of the eCRF. 
For TEAEs leading to study discont inuation, a s umm ary by [CONTACT_435247]. 
AEs leading to study discontinuatio n will be listed. 
14.1.3. SERIOUS ADVERSE EVENTS 
Serious adverse events (SAEs) are those ev ents recorded as "Serious " on the Adve rse Events page of the (e) CRF . 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga -PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003103] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 25/49Statist ical Analys is Plan 
A summary of serious TEAEs by [CONTACT_435247]. 
Serious AEs will be listed. 
14.1.[ADDRESS_1003104] ications 
PROTOCOL A206D-A0 1-001 
Page 25 of 48 
TEAEs leading to Death are those events which are recorded as "Fatal" on the Adverse Events page of the (e)CRF . 
A summary ofTEAEs leading to death by [CONTACT_435247] . 
AEs leading to Death will be listed. 
14.2. LABORATORY EVALUATIONS 
Results from the local laboratory will be inc luded in the report ing of this study for Hematology, Blood Chemistry 
and Urinalysis. A list of laboratory assessme nts to be included in the outputs, and a severi ty grading system is 
included in APPENDIX 3. 
Presentat ions will use SI Units. 
Quant itative labora to1y meas ureme nts report ed as"< X", i.e. below the lower limit of quant ification (BLQ ), or 
"> X", i.e. abov e the upper limit of quantification (ULQ), will be converted to X for the purpose of quantitative 
summ aries, but will be presented as recorded, . i.e. as "< X" or "> X" in the listings. 
The following summaries will be prov ided for laboratory data: 
• Observed values and change from baseline by [CONTACT_765] (for quant itative measurements) 
• Summary of qualitative clinical laboratory evaluation s by [CONTACT_765] 
• Incidence of abnorm al values at any time post-base line according to normal range criteria 
• Shift from basel ine accord ing to normal range crite ria (for quantitative measurements and categorical 
measureme nts), by [CONTACT_765] 
• Shift from baseline to worst post-baseline value, accord ing to sever ity gradi ng system 
• Summary of markedly abnormal post-basel ine values 
• Listing of patients with Grade 3 or above sever ity grades 
• Box plots of absolute values over time and changes from baseline over time 
14.2 .1. LABORATORY REFERE NCE RANGES 
Quantit ative laboratory measurements will be compa red with the relevant laboratory reference ranges and 
categor ized as: 
• Low : Below the lower limit of the laboratory reference range. 
• N orma l: With in the lower and upper limits of the laborato ry reference range. 
• High: Above the upper limit of the laboratory reference range. 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _BS0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003105] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 26/49Statistical Analys is Plan 
14.2.2. SEVERITY GRAD ING FOR LABORATOR Y DAT A 
Labo ratory results will be classified accord ing to Advanced Accelerator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 26 of 48 
• The Toxicity Grading Scale for Healthy Adult and Adolescem Volunteers Enrolled in Preventive Vaccine 
Clinical Study. 
• The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 
• The University of Delaware Criteria 
The "Grade O" will be in trodu ced to indicate that a certa in laboratory value can be s een as "norma l" and does not 
fulfill the criteria of severity grading eithe r within the reference range or elevated in the other direction than defined 
in the APPENDIX 3. 
Param eters flagged as "Medical Adviso r Input Needed" in APP ENDIX 3, will be graded as per medical advi sor 
identificat ion based on listings provi ded . 
14.3. ECG EVALUATIO NS 
Results from the ECG (Electrocardiogra m) will be included in the reporting of this study. 
The following ECG parameters will be reported for this study: 
• RR Interval (msec) 
• PR Interval (msec) 
• QRS Interval (msec) 
• QT Interval (msec) 
• QTcF Interval (msec) 
• QTcB Interval (msec) 
• Overall interpretat ions of ECG (Inve stigator's judgm ent): 
o Normal 
o A bnormal, Not Clinically Significant 
o A bnormal, Clinically Significant 
The following summaries will be prov ided for ECG data: 
• Actual and change from baseline by [CONTACT_765] (for quant itative measure ments) 
• Incidence of mark edly abnormal post-basel ine values at any time post-basel ine. 
• Shift from baseline accord ing to worst overall interpre tation 
• Box plots of absolute values over time and changes from baseline over time 
• L isting of patients meeting markedly abno rmal criteria 
The handling of retest s, unschedul ed and end of study measurement s is described in Section 6.4. 
14.3 .1. ECG MARKEDLY ABNORMAL CRITER IA 
Markedly abnormal quantitative ECG measurements will be ident ified in accordance with the following 
Docu ment: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostatistics\Documentation\SA P\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003106] ive Date : 01Apr2018 Version Date: 29JUN2020 
Reference: CS_WI_BS 005 
 
 

8/11/[ADDRESS_1003107] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 27/49Statist ical Analys is Plan 
predefined markedly abnormal criteria: Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 27 of 48 
• Absolute values for QT interval, QTcB interval and QTcF will be classified as: 
o > 450 msec 
o > 4 80 msec 
o > 500 msec 
• Change from Baseline for QT interval, QTcB interval and QTc F will be classified as: 
o >30 msec increase from base line 
o >60 msec increase from base line 
14.4. VITAL SIGNS 
The following Vital Signs measurements will be reporte d for this study: 
• Weight (kg) 
• Systo lic Blood Pressure (mmH g) 
• Diasto lic Blood Pressure (mm Hg) 
• Te mperature (0C), cons idering that °C = (°F -32) / 1,8 
• Heart Rate (bpm) 
• R espi[INVESTIGATOR_13581] (resp/ min) 
The following summaries will be provided for vital signs data: 
• Actual and change from baseline by [CONTACT_765] 
• Incidence of markedly abnormal values at any time post-baseline 
• Shift from baseline accord ing to mark edly abnormal criter ia by [CONTACT_765] 
• Box plots of absolute values over time and changes from baseline over time 
• Listing of patient s meeting markedly abnorm al crite ria 
The handling of retests, unschedu led and end of study measure ments is describe d in Section 6.4. 
A list of Vital Signs measurem ents to be included in the outpu ts, and a sever ity gradi ng system is included in 
APPENDIX 4. 
14.5. ECOG 
ECOG performance status at baseline and post-basel ine visits will be listed on the FAS. 
15. BIODISTRIBUTION , DOSIMETRY AND IMAGING OF 68GA-PSMA-R2 
Biodi stribution is defined as the activ ity in various orga ns over time quantified by [CONTACT_9661]. Dosimetry is the 
assessment of radiation dose per unit admini stered activity. 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP \v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _BS0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003108] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 28/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-[ADDRESS_1003109], MRJ and/or bone scans. 
A list of tests and organ s to be included in the outputs is included in APPENDIX 5. 
15.1. ANALYSES OF BIODISTRIBUTION AND DOSIMETRY 
For phase I, PET and convention al scans will be performed on D ay I at 20-[ADDRESS_1003110]-injection. For Phase II, all patient s will undergo whole body PET and conventional scans optimized for time 
(up to 2 time points) according to the data analy sis from the Phase I component of the study. Further details about 
imaging assess ments can be found in the sectio n 6.5.4 of the protocol. 
Data from the radiation dosimetry vendor will be presented using SI Units and the following statistical summaries 
will be prov ided: 
• Decay corrected tissue activity in normal organs by [CONTACT_734094] 
• Non-decay corrected tissue activity in normal organs by [CONTACT_336079] 
• R esidence times in norm al orga ns 
• Absorbed doses, whole body dose and effective dose of 68Ga -PSMA -R2 in norm al organs 
Time Activity Curve (TAC) will be produced as graph ical representation of Decay corrected tissue activity and 
Non-decay corrected tissue activity. 
15.2. ANALYSES OF IMAGI NG 
15.[ADDRESS_1003111] uptak e value (SUV) will only be available in PET scans. 
Descriptive analysis will be performed on SUV and the following summaries will be produ ced: 
• SUV max, SUV mean and TBR with positive lesio n s tatus in PET scan 
• SUV max, SUV mean and TBR with positive lesion status in PET scan and correlated with conventional scan 
• SUV max, SUV mean and TBR with positive lesion status in PET scan and not correlate d with conventional 
scan 
Lesion Tumor to Background Ratio (TBR) is defined as SUVmaX (1es;on) / SUVmean <g1u1ea1 orlh;ghJ and will be 
summarized in the same way as SUV max and SUV mean. 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003112] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 29/49Statistical Anal ysis Plan Advanced Accelerator Applications 
PROTOCOL A206D -A01-001 
Page 29 of 48 
15.2.2. LESIONS DETECTED BY [CONTACT_734095] A N D/OR CONVENTIONAL SCAN, BY [CONTACT_734096] P ET scan, correlated or not with conventional scan, will be presen ted 
by [CONTACT_734097]. 
15.2.3. BURDEN AND LOCATION OF TUMOR LESIONS DETECTE D BY 68GA-PSMA-R2 IN COMPAR ISON 
W ITH CONVENT IONAL IMAG ING MODAL ITIES SUCH AS CT /MRI AND /OR BONE SCAN. 
• T he diffe rence of number of lesio ns detected by 68Ga-PS MA-R2 P ET scan and by [CONTACT_734098]/ MRI and/or bone scan, will be di splayed by [CONTACT_734099] n. T he number of lesions 
detected on the PET scan, correlated and not correlated with conve ntional scan les ions, will be prese nted. 
T he number of lesions detec ted on the conventional scan, not correlated with lesio ns detected on the PET 
scan, will be presented. 
• T he differe nce in the number of posit ive patients detec ted by 68Ga-PSMA- R2 PET and by [CONTACT_734100]/MRI and/or bone scan, wi ll be displayed by [CONTACT_734099] n. T he numb er of positive 
patients detected on the PET scan, with at least [ADDRESS_1003113] 1 lesio n not correlated 
with a lesion detected on the conventio nal s can, will be presented. The numbe r of positive patien ts 
detected on the conventio nal scan, with no lesio ns correla ted with any lesion detecte d on the PET scan, 
will be presente d. Note: A posit ive patient has at least [ADDRESS_1003114]. 
68GA-PS MA-R2 
PET Scan 
Total + Convent ional Scan 
+ 
a 
C 
a+c b 
d 
b+d 
The patient-level posit ive perce nt agree ment, negative percent agr eeme nt and overa ll perce nt agreeme nt will be 
calculated based on the num ber of patie nts with at least one posit ive lesion detected by [CONTACT_734101] s can and/or at 
least one positive lesion detect . ed by [CONTACT_60864]. 
Docu ment: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics\Documentation\SAP\v2.0\ Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.[ADDRESS_1003115] ate No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_Wl_BS 005 
 
 

8/11/[ADDRESS_1003116] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 30/49Statist ical Anal ysis Plan Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 30 of 48 
These percent agreements will be calculated as follows with their two-sided 95% score confidence intervals: 
• Positive percent agreement: a/(a+c) * 100 
• Negative percent agreement: d/(b+d) * I 00 
• Overall percent agreement: (a+d)/(a +b+c+d ) * I 00 
Where 
• a is the number of patients with al least one positive lesion detected by [CONTACT_734102] 
• bis the number of patients with at least one positive lesion detected by [CONTACT_734103] 
• c is the number of patients with at least one positive lesion detected by [CONTACT_734104] 
• d is the number of patients with no lesions detected by [CONTACT_734105] 3 coeffic ients and their 95% Clopper Pearson Exact confidence interva ls will be calculated using SAS PROC 
FREQ as follow : 
PROC FREQ data=temp; 
tables resp/binomial (exact level =']'); 
RUN; 
The lesion-level positive perce nt agreement and overall percent agreement will be calculated based on the number of 
lesions detected as positive by [CONTACT_734106] l scan and/or by [CONTACT_60864] . 
These percent agreements will be calculated as followes with their two-sided 95% score confidence intervals: 
• Positive percent agreement: a/(a+c) * I 00 
• Overall percent agreement: (a)/(a +b+c) * I 00 
Where 
• a is the number of lesions detected as positive in both PET and conventional scan 
• bis the number of lesions detected as positive in PET scan but not correlated with convent ional scan 
• c is the number of lesions detected as positive in convent ional scan but not correlated with PET scan 
These 2 coeffic ients and their 95% Clopper Pearson Exact confidence interval s will be calculated using SAS PROC 
FREQ as above. 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS WI_BS005 
 
 

8/11/[ADDRESS_1003117] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 31/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-[ADDRESS_1003118] of lowercase letters, digits (0 to 9) and hyphens. A period should only be used to 
indicate a separator between the file name [CONTACT_734117]. No spaces, other spec ial characters or punctuation marks 
are permitted. 
The program, program log and output file name [CONTACT_210068] d reflect the type of the statistical output. The output files will 
contain the output numb er in addit ion. If this is not poss ible, then the output name [CONTACT_734118]. A prefix can be used to distinguish betw een a Table, Listing and Figure docum ent ('t' for table, '1' for listing 
and 'P for figure). If there is only I digit in the number of the tab le, listing or figure in the place where 2 digits are 
possible, a leading zero should be added in the file name [CONTACT_734119] (e.g. t-14-3-01-
1.RTF) 
As far as possible, output files should be in RTF and PDF format. 
The outputs will be provided in pdf format. 
PAPER SIZE, ORIENTATIO N AND MARGI NS 
The size of paper will be Letter. 
The page orientation should preferably be landscape, but portra it is also permitted. 
Marg ins should prov ide at least 1 inch (2.54 centimeters) of white space all around the page, regardless of the paper 
size. 
The numbe r of columns per page (linesize) should be 134 for Letter. 
The numbe r of rows per page (pagesize) should be 40 for Letter. 
FONTS 
The font type 'Cout~er New' shou ld be u sed as a default for tables and listin gs, with a font size of 8. The font color 
should be black. No bolding, underlining italics or subscripting should be permitte d. Try to avoid using super-scripts, 
unless absolutely necessary. Single spac ing should be used for all text. 
Figures shou ld have a d efault font of"Times Roman ", "Helvetica", or "Courie r New". 
This can be achieved by [CONTACT_734107]: 
goptions 
gunit = pct 
cback = white 
colors = (black) 
hby = 2.4 
ftext = "I imesRoman " 
htext = 2.5; 
Document: K:\AM\ Ga-PSMA-R2 \VYA27826 \ Biostat istics\Documentation \SAP\v2.0 \Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003119] ive Date: 01Apr2018 Version Date: 29JUN2020 
Reference: CS_WI_BS005 
 

8/11/[ADDRESS_1003120] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 32/49Statist ical Analys is Plan 
HEADER INFORMATIO N 
Heade rs should be defined as follows: Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 32 of 48 
• T he header should be placed at the top of the page (same pl ace on each page) regardle ss of the size or 
orientat ion of the table or listing 
• The customer name [CONTACT_734120] I, left-aligned 
• T he output identification number should appear in row 2, left-aligned 
• The output title should start in row 2 after output identification number separated by a double dot, left-aligned 
• T he output populat ion should appear in row 2 after output title separated by a dash, left-aligned. The 
population should not be spelle d out in full, e.g. FAS in preference to Full analysis set. 
• Row 3 s hould be a continuous row of underscores (' _ ')(th e numbe r of underscores should equal the linesize) 
• R ow 4 should be a blank line 
• Mixed case should be used for titles 
• The output titles should be designed so that they are arranged consiste ntly through all outputs. For example, 
content (e.g. Vital Signs) followed by [CONTACT_375678] (e.g. Change from Baseline) e.g. Vital Signs -Change from 
Baseline. 
• T itles should not contain quotat ion marks or footnote references 
• The column headi ngs shou ld be underlined with a row of underscores ('_') 
• Column headings spann ing more than one colu mn should be unde rlined and have underscores on either side 
of the title and should be centered 
• Column headings containing numb ers should be centered 
• Column headings should be in sentence case 
• In general, the population count shou ld appear in the column header in the form "(N=XXX)" 
• "Stat istic" should be the column header over n, Mean, SE, n (%) etc. 
• As a rule, all columns should have column headings. 
TABLE AND LISTING OUTPUT CONVENTIONS 
General: 
• T he first row in the body of the table or listing should be blank 
• T he left-hand column shoul d start in column I . No inden ting or centeri ng of the output should occur. 
• R oundin g should be done with the SAS function ROUND , if no further specification . 
• Numb ers in tables shou ld be roun ded, not truncated, if no further specification. 
• Al phanumeric output should be left aligned. 
• Number s should be decimal point aligned. 
• Whol e numbers should be right aligned. 
• T ext values should be left aligne d. 
• The first letter of a text entry should be capi[INVESTIGATOR_057] 
• Listin gs of adverse events, concom itant medic ations, medical histor ies etc. shoul d be sorted in chrono logical 
order, with earliest adverse event, medication or history coming first. 
• The study drug should appear first in tables with treatments as columns 
• In general, only present totals (across treatment groups) at baseline/random izatio n, and do not present them 
post random ization. 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003121] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 33/49Statist ical Analys is Plan Advanced Accel erator Appl ications 
PROTOCOL A206D-A0 1-001 
Page 33 of 48 
• If possible, include 100% frequencies in the table sh ell, so that it is clear what the denominator is for 
percentage calculat ions. 
• A ll listing output s shou ld be sorted (preferab ly by [CONTACT_75891], Site Number and Patient Number). 
• Do not use superscr ipts and subscripts 
• The widt h of the entire output should matc h the linesize 
Univariate Statistics: 
• Statistics should be presented in the same order across tables (i.e., n, Mean, Std Dev, Median, QI, Q3, 
Minimum , Maximum or n, gMean, gCV, Mean, CV, Std Dev, Median, Minimum, Maximum ) 
• T able statistics should line up under the N part of the (N=XXX) in the table heade r. All decimal points shou ld 
line up. If the minimum and maximum are output on one line as Minimum, M aximum then the comma shou ld 
line up with the decimal point. 
• If the original data has N decimal places, then the summary statistics should have the following decimal 
places: 
o Minimum and maximum: N 
o Mean, gMea n, QI, Q3, medi an, gCVo/o and CV%: N + I 
o Std Dev: N + 2 
Frequencies and percentage s (n and%): 
• Percent values should be reported inside parentheses, with one space betwee n the count and the left 
parenthe sis of the percentage. Parentheses should be j ustified to accept a maximum of I 00.0 as a value and 
padded with blank space if the percent is less than I 00.0. An example is give n below: 
77 (100.0 %) 
50 (64.9%) 
0 (0.0%) 
• Percentages will be reported to one decima l place, except percentages < I 00.0% but >99. 9% wi II be prese nted 
as '>99 .9%' (e.g., 99.99% is presented as >99.9%); and percentages< 0.1% will be present ed as '<0.1%' 
(e.g., 0.08 % is presented as <0. I%). Rounding will be applied after the <0.1 % and >99.9% rule. 
E.g. ( <0. I%) 
(6.8%) 
(>99.9%) 
• Percentages may be repo rted to 0 decimal places as appropr iate (for example, where the denominator is 
relat ively small). 
• Where coun ts are zero, percentages of 0.0% shou ld appea r in the outpu t. 
Confidence Intervals: 
• As a rule, confiden ce intervals are output to one place more than the raw data (except for the primary analysis 
where we compare agains t a margin with 3 decima l places ), and standard deviations and standard errors to 
two places more than the raw data 
• Confidence intervals should be justified so that parentheses display ed on consec utive lines of a table "line 
up". 
• B oundary values of confidence intervals should be separated by a semi-colon. 
• Boundary values shoul d be padded as necessary to accept negat ive values and to allow alignment of the 
decimal place. 
• An example is given below: 
(-0.12; -0.10) 
(9.54; 12.91) 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP \v2.0\Ga-PSMA -R2-SAP _v2.0 
Author: Version Number: 2.0 
 
Template No.: CS_TP _BS0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_Wl_BS005 
 
 

8/11/[ADDRESS_1003122] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 34/49Statist ical Anal ysis Plan 
P-values: Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 34 of 48 
• P- values should be reported to four decimal places, Rounding will be applied after the <0.0001 and >0.9999 
rule 
Ratios: 
• Ratios should be reported to one more decim al place than the original data. 
Spacing: 
• T here must be a minimum of I blank space between columns (prefera bly 2) 
Denom inators : 
• If a different count other than the populat ion count is used for a denominator (within the table) to calculate 
percentages, there shou ld be a row in the table that identifies th at number "n". 
• Al ternatively, a footnote should be included in each table with percentages to indicate the denominator for 
percentages. 
Missing values 
• A "0" should be used to indicate a zero frequency. 
• A blank will be used to indicate missing data in an end-of-text table or patient listing. 
FIGURE OUTPUT CONVENTIONS 
• Figures will be provided in RTF and PDF files using the SAS Output Delivery System (ODS) as generated 
by [CONTACT_78718]. 
• T he image should be clear and of high qual ity when viewed in the Word document , and when printed. 
• In general, boxes around the figures should be used. 
• Boxplots will display whiskers extending from PlO to first quart ile and from 3rd quartile to P90. 
FOOT NOTE INFORMATIO N 
Footers shou Id be defined as follows: 
• A continuous line of unde rscores(' _') will follow the body of the table or listin g prior to any footnot es at the 
bottom of the page 
• T able footnotes should be defined using compute statements in the proc report, and should appear directly 
after the body of the table 
• T he program path and name [CONTACT_734121] (if applicable ) should appear as footnote 1 at the bottom of 
the page 
• T he date/time stamp shou ld appear as footnote 2 at the bottom of the page 
• Footnotes should be left-aligned . 
• Footnotes should be in sentence case. 
• Only "typewTiter" symbols are permitted -e.g."*","$","#","@","&" and"+". 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _BS0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003123] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 35/49Statist ical Anal ysis Plan Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-001 
Page 35 of 48 
• T he choice of footnote symbols shou ld be consist ent. E.g. if you have the footnot e "# indicates last 
observation can-ied forward" for one table, the same symbol and footnote should indicate LOCF for all tables . 
• If text wraps across more than one line (for a note), the first letter for all lines of text after the first one will 
be indented to align beneat h the first letter of the text in the first line. 
• T he page identificat ion in the format Page X of Y (where Y is the total number of pages for the output) should 
appear in the footer, right aligned . 
Ordering of footnotes shou Id be as follows: 
I.) Source data listing reference, if nece ssary 
2.) Abbreviations and definitions 
3.) Formulae 
4.) P-value significance footnote 
5.) Symbo ls 
6.) Spec ific notes 
• Common notes from table to table shou ld appear in the same order. 
The symbols shou ld appear in the same order as what they are defined in the table or listing, from left to right. 
DATES & TIMES 
Depending on data available, dates and times will take the form yyyy -mm-ddThh :mm:ss. 
SPELLING FOR MAT 
English US. 
PRESENTATIO N OF POPULATIO N GROUPS 
For outputs, population groups will be represented as follows and in that order: 
Population Group For Tables, Listings and Graphs 
PCa-BR PCa-BR 
mPCa mPC a 
PCa-BR + mPCa Overall 
PRESENTATION OF VISITS 
For outputs, visits will be represented as follows and in that order : 
Document: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics \Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003124] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 36/49Statistical Anal ysis Plan 
Long Name (d efault) 
Screening 
Baseline (D ay I) 
Day7 
Day28 
LISTINGS Shor t.Na me 
Screening 
D I 
D7 
D28 Advanced Accelerator Applications 
PROTOCOL A206D -A01-001 
Page 36 of 48 
All listing s will be or dered by [CONTACT_716] (unless otherwise indicated in the template): 
o P opulation group 
o center -patient ID, 
o date (where applicable) 
Docu ment: K:\AM \Ga-PSMA -R2\VYA27826 \ Biostatistics\Documentation\SAP\v2.0\ Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.[ADDRESS_1003125] ate No.: CS_TP _8S0 [ADDRESS_1003126] ive Date : 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS 005 
 
 

8/11/[ADDRESS_1003127] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 37/49Statist ical Anal ysis Plan Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-[ADDRESS_1003128] ATE CANCER HISTORY 
P . Id art1a ate to e ,mout b . ed as: 
Start date Earliest possible date first day of month if day unknown 
or I st January if day and month are 
unknown 
Stop date Latest possible date last day of month if day unknown 
or [ADDRESS_1003129] December if day and month 
are unknown 
ALGORI THM FOR PRIOR/ ACTIVE PROCEDURES, RADIOTHE RAPI[INVESTIGATOR_5165], CANCER THER API[INVESTIGATOR_734073] 
P . Id artia ate to b ed e JmPUt as: 
Start date Earliest possible date first day of month if day unknown 
or I st January if day and month are 
unknown 
Stop date Latest poss ible date last day of month if day unknown 
or [ADDRESS_1003130] December if day and month 
are unknown 
General rules: 
If start date <= study med start date, assign as prior 
If stop date> = study med start date, assign as concomitant 
If Missing Stop date: (Rules 2) 
If stop date is missing, assign as prior and concom itant 
If Missing Start date: (Rules 3) 
If stop date < study med start date, assign as prior 
If stop date> = study med start date, assign as prior and concomitant 
Document: K:\AM\Ga -PSMA -R2\VYA27826 \ Biostatistics \Documen tation\ SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date: 29JUN2020 
Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003131] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 38/49Statist ical Analys is Plan 
START STO P 
DATE DATE 
Known Known 
Partial 
Missing 
Partial Known 
Partial 
Missing 
Missing Known 
Partial 
Missing ACTION 
General rules 
General rules 
General rules 
General rules 
General rules 
Rules [ADDRESS_1003132] ications 
PROTOCOL A206D-A0 1-001 
Page 38 of 48 
ALGORITHM FOR TREATMENT EMERGENT OF ADVERSE EVENTS 
STA RT DATE STOP ACTION 
DAT E 
Known Known If start date < study med start date or start date> actual date of 
Partial last follow up visit, then not TEAE 
Missing If start date> = study med start date and start date <= actual 
date of last follow up visit, then TEAE 
Partial, but known Known NotTEAE 
components show that it Partial 
cannot be on or after study 
med start date Missing 
Partial, could be on or after Known Impute start date as earliest poss ible date, (i.e. first day of 
study med start date month if day unknown or I st January if day and month are 
unkn own), except if only day is missing and month and year 
of start date are the same as for study med start date or if day 
and month are missing and year of start date is the same as for 
study med start date. In the latter cases, the study med start 
date will be used for the imputa tion. 
If start date <= stop date, then: 
If stop date < study med start date, then not TEAE 
If start date> actual date of last follow up visit, then not 
TEA E 
Document: K:\AM\ Ga-PSMA-R2 \VYA27826 \ Biostat istics\Documentation \SAP\v2.0 \Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 16 Revision 5 
Effective Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003133] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 39/49Statist ical Analys is Plan 
START DATE STOP 
DATE 
Partial 
Missing 
Missing Known 
Partial 
Missing ACTION Advanced Accel erator Appl ications 
PROTOCOL A206D-A01 -001 
Page 39 of 48 
If stop date>= study med start date and start date <= 
actual date of last follow up visit, then TEAE 
If start date > stop date, then: 
Consider the start date as Missing and apply the algorithms 
for missing start date 
Impute start date as above. 
Impute stop date as latest poss ible date (i.e. last day of month 
if day unknown or 31st December if day and month are 
unkn own), if not resulting in a date later than the date of 
patient's death. In the later case the date of death will be used 
for imputation. 
If start date <= stop date, then: 
If stop date < study med start date , then not TEAE 
If start date> actual date of last follow up visit, then not 
TEAE 
If stop date>= study m ed start date and start date <= 
actual date of last follow up visit, then TEAE 
If start date > stop date, then: 
Consider the start and stop dates as Missing and apply the 
algorithms for missing start date 
Assumed TEAE 
If stop date < study med start date, then not TEAE 
If stop date> = study med start date, then TEAE 
Impute stop date as latest poss ible date (i.e. last day of 
month if day unknown or 31st December if day and month 
are unknown ), if not resulting in a date later than the date of 
patient's death. In the later case the date of death will be 
used for imputation : 
If stop date < study med start date, then not TEAE 
If stop date> = study med st art date, then TEAE 
Assumed TEA E 
Document: K:\AM\ Ga-PSMA-R2 \VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Author:  Version Number: 2.0 
 
Template No.: CS_TP _8S0 [ADDRESS_1003134] ive Date: 01Apr2018 Version Date : 29JUN2020 
Reference: CS_WI_BS005 
 
 

8/11/[ADDRESS_1003135] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 40/49Statist ical Anal ysis Plan 
ALGORITHM FOR PRIOR/ CONCOMITANT MEDI CATIONS 
P . Id art1a ate to e 1mput b . ed as: 
Start date Earlie st possible date 
Stop date Latest possible date 
General rules: 
If start date <= study med start date, assign as prior 
If stop date> = study med start date, assign as conco mitant 
If Missing Stop date: (Rule 2) 
If stop date is missing, assign as prior and conco mitant 
If Missing Start date: (Rule 3) 
If stop date < study med start date, assign as prior Advanced Accel erator Appl ications 
PROTOCOL A206D -A01-[ADDRESS_1003136] day of month if day unknown 
or I'' January if day and month are 
unknown 
last day of month if day unknown 
or 31" December if day and month 
are unknown 
If stop date >= study med start date, assign as prior and concomitant 
START STOP ACTION 
DATE DATE 
Known Known General ru Jes 
Partial General rules 
Missing Rule2 
Parti al Known General rules 
Partial General rules 
Missing R ule2 
Missing Known Rule3 
Partial Rule3 
Missing Rule2 
Document: K:\AM\ Ga-PSMA -R2\VYA27826 \ Biostat istics\Documentation \SAP\v2.0\Ga-PSMA -R2-SAP _v2.0 
Autho r:  Version Number: 2.0 
 
Version Date: 29JUN2020 
Template No.: CS_TP _8S0 [ADDRESS_1003137] ive Date : 01Apr2018 Reference : CS_WI_BS005 
 
 

8/11/[ADDRESS_1003138] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 41/49Statistical Analysis Plan 
APPENDIX 3. LABORATORY ASSESSMENTS 
a) Graclab le with Toxicity Gradi ng Scale for Healthy Adult and Aclol, 
Volunteers Enro lled in Preventive Vacci ne Clinical Study 
b) Gracl able w ith Common Terminolo gy Criteria for Adver se Even ts 
Version 4.03 
Labora tory parameter Gradin g c) Graclab le with University of Del aware Criter ia Scale (htti:1://wwwl .udel.edu/mls/ mclane/KMS3 RR.htm l) 
cl) Not Graclable 
Mark edly Abn or 
Grad e l Grad e 2 Grade 3 
Blood chemistry I 
ALT/ ALAT a >=I. [ADDRESS_1003139] -<2.5 >=2.[ADDRESS_1003140]- >= 5.0x ULN ->= 10x 
X ULN < 5.0x ULN <[ADDRESS_1003141]/ ASAT a >=I. I x U LN -<2.5 >= 2.[ADDRESS_1003142]- >= 5.0x ULN ->= 10x X ULN < 5.0x ULN <[ADDRESS_1003143] 
Gamma glutamyl transpep tidas e (g- GT) b >= [ADDRESS_1003144]- >= 2.[ADDRESS_1003145]- >= 5.[ADDRESS_1003146] ->=20.0 <2.[ADDRESS_1003147] <5.[ADDRESS_1003148] <20.[ADDRESS_1003149] 
(Liver Funct ion test norma l*) a >=l.lxU LN- >= 1.[ADDRESS_1003150] - <1.5 >=1.[ADDRESS_1003151] ->= 1.75 <1.[ADDRESS_1003152] <1.[ADDRESS_1003153] Total bilirubin (Liver Funct ion test a >= I. [ADDRESS_1003154] -< 1.5 >=1.[ADDRESS_1003155] - >=2.[ADDRESS_1003156] ->= 3.0: increase* ) X ULN <2.[ADDRESS_1003157] <3.[ADDRESS_1003158] 
AP (ALP) a >=I. [ADDRESS_1003159] -<2.0 >=2.[ADDRESS_1003160] - >=3.0x ULN ->= 10x 
X ULN <3.[ADDRESS_1003161] <[ADDRESS_1003162] 
BUN a >=8.211 -<9.75 >=9.75 -<11.62 5 >= 11.625 mmol /L Require mmol/L mmol/L 
Total prote in a >55 -<=60 g/L >50-<=55 g/L <= 50 g/L NA 
Albumin a >27 -<=31 g/L >25 -< =27 g/L <=25 g/L NA 
Hyperglycemia a >=5.55 -<6.105 >=6. 105 -<6.9375 >=6.9375 mmol/L Insulin 
Glucose mmol/L mmol/L hype rm 
Hypoglycemia a >=3.6075 -<3.829 5 >=3.05 25 -<3.6075 >=2.4975 -<3.0525 <2.497'. mmol/L mmol/L 11111101/L 
eGFR (Any eGFR value >90 will be class ified as b <=90 ->60 ml/min/ <=60 ->30 ml/mi n/ <=30 - > 15 ml/min / <= 15 ff Grade 0) 1.73 m2 1.73 1112 1.73 m2 
LDH d NA NA NA NA 
Document: 
Author: K:\AAA\Ga-PSMA-R2 \VYA27826 \Biosta tistics\Documentat ion\SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Temp late No.: CS_TP _B8016 Revision [ADDRESS_1003163] ive Date: 01 Apr201 8 \ 
F 
 
 

8/11/[ADDRESS_1003164] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 42/49Statistical Analysis Plan 
a ) Graclab le with Toxicity Grading Scale for He althy Adult and Aclol, 
Volunteers Enrolled in Preventive Vacci ne C linical Study 
b) Graclab le with Common Terminolo gy Criteria for Adve rse Events 
Version 4.03 
Laborator y para met er Gradin g c) Gracl a ble w ith University of Delawa re Crite ria Scale (ht111://wwwl .udel.edu/ mls/mclane/KMS3RR.htm l) 
cl) Not Graclable 
Markecl lv Abnor 
Graci e l Graci e 2 Gracie 3 
Hypercalcemia a >=2.625 -<2.75 >= 2.75 -<2.875 >=2.875 -<3 >= 3 l1l Corrected mmol/L mmol/L mmol/L 
Calcium 
Hypoc alcemia a >=2 -<2.1 mmol/L >=1.875 -<2 mmol/L >=1.75 -<l.875 <1.75 11 mmol/L 
Serum creatinine a >= 132.6 - < 1 50.28 >=150.28 -<176 .8 >=1 76.8 - <221 >=221 
umol/L umol/L umol/ L require: 
Hypernatrem ia a >=144 -<145 >= 145 -<147 mmol/L >=147 -<150 >=)50 I 
Sodium mmol/L mmol/L 
Hyponatremi a a >=132-<134 >=130-<132 >=125 -<130 <125 Ill mmol/L mmol/L mmol/L 
Hyperkalemia a >=5.1 -<5.2 >=5.2 -<5.4 mmol/L >=5.4-<5.6 >= 5.61 
Potass ium mmol/L mmol/L 
Hypoka lemia a >=3.5-<3.6 >=3.3 -<3.5 mmol/L >=3.1 -<3.3 < 3.1 m mmol/L mmol/L 
>ULN -10 mg/dL >ULN -10 mg/dL 
Uric acid b (0.59 mmol/L) NA (0.59 mmol/L ) with >10 mg 
without physiologic physiologic mmol /1 
conse quen ces consequences 
Chloride d NA NA NA NA 
Hematology I 
RBC d NA NA NA NA 
Increased a >=10.8 - <15 >=15 -<20 10"9/L >=20-<25 10"9/L >=251 WBC 10"9/L 
White blood Decreased a >2.5 - <= 3.5 10"9/L > 1.5 - <= 2.5 I 0"9/L > I - <=1.5 10"9/L <= I IC 
cells with 
different ial Monocyt es d NA NA NA NA 
Eosinophils a >=0.65 - <1 .5 >=1.5 -<5 10"9/L >=5 10"9/L Hypere 10"9/L 
Document: 
Author : K:\AAA\Ga-PS MA-R2 \VYA27826 \B1osta t1st1cs \Documentat1on \SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effective Date: 01 Apr201 8 \ 
F 
 
 

8/11/[ADDRESS_1003165] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 43/49Statistical Analysis Plan 
a) Gracl able with T oxicity Grading Scale for Healthy Adu lt and Aclol, 
Volunteers En rolled in Preventive Vaccine C linical Study 
b) Graclab le with Common Terminol ogy C riteria for Adverse Even ts 
Vers ion 4.03 
Laboratory parameter Gradi ng c) Gracl able with U niversity of Delaware Criteria Scale (ht111://wwwl .udel.edu/ mls/mclane/KMS3RR.html) 
cl) Not Graclable 
Mark ecllv Abnor 
Graci e l Graci e 2 Gracie 3 
Basophil s d NA NA NA NA 
Lymphocytes a >0.75 -<=1 10"9/L >0.5 - <=0.75 10"9/L >0.25 - <=0.5 <= 0.25 10"9/L 
Neutrophil s a > 1.5 - <=2 1 0"9/L > 1 - <= 1.5 10"9/L >0.5 - <= 1 10"9/L <= 0.5 
Platelets a >125 - <= 140 
10"9/L > 100- <= 125 10"9/L >25 - <=100 10"9/L <= 25 1 
(Male) - gm/ dl a > 12.5 -<=13.5 > 10.5 - <=12 .5 >8.5 -<=10.5 <= 8.5 
Hb (Male) chan ge from 
baseline value - gm/ dl a Any decrease - > 1.5 >=1.5 ->2.0 >=2.0- <5.0 >= 5.0 
MC V d N A NA NA NA 
Hematocrit d NA NA NA NA 
PSA d NA NA NA NA 
Urinal ysis I 
Appearance d NA NA NA 
Color b D iscoloration NA N A 
pH d NA NA NA 
Speci fic gravi ty d NA NA N A 
Glucose a Trace 1+ 2+ Hospi[INVESTIGATOR_734074] d NA NA NA 
RBC/hpf 
WBC/hpf 
Casts/I pf >= 50 and/or gross H ospi[INVESTIGATOR_17399] 
a >=l -<10 >=10 -<50 packed blood (PRBC) 
C NA NA NA NA 
C NA NA NA NA 
Documen t: 
Author : K:\AAA\Ga-PSMA-R2 \VYA2 7826\Biosta tistics\Documentation\SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effective Date: 01 Apr20 18 \ 
F 
 
 

8/11/[ADDRESS_1003166] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 44/49Statistical Analysis Plan 
a) Graclab le with Toxicity Grading Scale for He althy Adult and Aclol, 
Volunteers Enrolled in Preventive Vacci ne C linical Study 
b) Graclab le with Common Terminolo gy Criteria for Adve rse Events 
Version 4.03 
Laborator y paramet er Gradin g c) Gracl able w ith University of Delaware Crite ria Scale (ht111://wwwl .udel.edu/ mls/mclane/KMS3RR.html) 
cl) Not Graclable 
Markecl lv Abnor 
Graci e l Graci e 2 Gracie 3 
Prote in (dipstick test accepted) a Trace I+ 2+ Hospi[INVESTIGATOR_734075] 
* This is not specified in FDA guidance. Therefore , we take as reference to the Hy's Law criter ia for potent ial 
Function parameter s to be taken in to account are Aspartate transaminase (AST ) and Alan ine transaminase ( Al 
Document: 
Author : K:\AAA \Ga-PSMA-R2 \VYA27826 \Biosta tistics \Documentation \SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effective Date: 01 Apr201 8 \ 
F 
 
 

8/11/[ADDRESS_1003167] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 45/49Statistical Analysis Plan 
APPENDIX 4. VITAL SIGNS MEASUREMENTS 
Gradable with Toxici ty Grading Scale for Healthy Adult and Adolescen t \ 
Grading Preventive Vaccine Clinical Study 
Vital Sign parameter Gradable with Common Terminol ogy Criter ia for Adverse Events (CTCAE 
Scale Markedly Abnorma l 
Grade 1 Grade 2 Grade 3 Grade 4 
>=38.0 -<38.S >=38.5 -<39 °C Temperatu re (0C), considering o c 
>=101.1- <102.0 >=39.0 -<40 °( >= 40 °( 
that °C = (°F -32) / 1,8 a >=100.4- >=102.0 -<104 °F >= 104 °F 
<101.1 °F O F 
Resp iratory Rate (resp/m in) a >=17-<20 >=20- <25 >= 25 Intubation 
Weig ht gain b >=5 -<10% >=10-<20% >= 20%from 
from base line from baseline baseline NA 
Weight >=5 to <10% >= 10 to <20% >=20% from 
baseline; tube (kg) Weig ht loss b from base line; from baseline; feeding or total NA intervention nutrit ional 
not indicated suppo rt indicated parenteral nutrition 
(TPN ) indicated 
Emergency 
Heart Tachycardia a >=101-<115 >=115-<130 >=130 visit or hos 
Rate for arrhyt h 
(bpm) Emergency 
Bradycardia a >50-< =55 >45 -<=50 <=45 visit or hos 
for arrhyt h 
Systolic Emergency 
Blood Hypertens ion >=141-<150 >=150-< 155 >= 155 visit or hos 
Pressure a for malignc 
(mmHg) hypertensi , 
Docume nt: 
Author : K:\AAA\Ga-PSMA-R2 \VYA27826 \Biosta tistics \Documentat ion\SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision [ADDRESS_1003168] ive Date: 01 Apr2018 \ 
F 
 
 

8/11/[ADDRESS_1003169] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 46/49Statistical Analysis Plan 
Gradab le with Toxici ty Grading Scale for Healthy Adul t and Adolescen t \ 
Grading Preventive Vaccine Clinical Study 
Vital Sign parame ter Gradab le with Common Termin ology Criteria for Adverse Events (CTCAE 
Scale Markedly Abnorma l 
Grade 1 Grade 2 Grade 3 Grade 4 
Emergency 
Hypotension a >85 -<=89 >80-< =85 <= 80 visit or hos 
for hypote1 
Diastol ic Emergency 
Blood Hypertens ion >=91- <95 >= 95-<100 >= 100 visit or hos 
Pressure a for maligm 
(mmHg) hypertensi , 
Document: 
Author: K:\AAA \Ga-PSMA-R2 \VYA27826 \Biosta tistics \Documentation \SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effective Date: 01 Apr20 18 \ 
F 
 
 

8/11/[ADDRESS_1003170] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 47/49Statistical Analysis Plan 
APPENDIX 5. DOSIMETRY MEASU REMENTS 
TEST Organs / Lesions 
Decay corrected tissue activity Brain 
Heart Wall 
Kidneys 
Lacrimal Glands 
Liver 
Lungs 
Red Marro w 
Salivary Glands 
Spleen 
Thyro id 
Urinary Bladder 
Lesion 1 
... 
Lesion 10 
Percent GI excretion 
Non-decay corrected tissue activity Brain 
Heart Wall 
Kidneys 
Lacri mal Glands 
Liver 
Lungs 
Red Marrow 
Salivary Glands 
Spleen 
Thyro id 
Urinary Bladder 
Lesion 1 
... 
Lesion 10 
Absorbed doses Brain 
Document: 
Author: K:\AAA \Ga-PSMA-R2 \VYA27826 \Biosta tistics \Documentation \SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effective Date: 01 Apr2018 \ 
F 
 
 

8/11/[ADDRESS_1003171] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 48/49Statistical Analysis Plan 
Heart 
Kidneys 
Lacri mal glan ds 
Liver 
Lungs 
Red Marrow 
Salivary glands 
Spleen 
Urinary Bladder 
Who le body dose 
Effective dose 
Lesion doses Lesion 1 
... 
Lesion 10 
Residence times Brain 
Heart 
Kidneys 
Lacri mal glan ds 
Liver 
Lungs 
Red marrow 
Salivary glands 
Spleen 
Thyro id 
Urinary bladder 
Remainder 
Lesion 1 
... 
Lesion 10 
Docume nt: 
Author : K:\AAA \Ga-PSMA-R2 \VYA27826 \Biosta tistics \Documentation \SAP\v2.0\Ga-PSMA-R2-SAP 
 \ 
Template No.: CS_TP _B8016 Revision 5 
Effectiv e Date: 01 Apr20 18 \ 
F 
 
 

8/11/[ADDRESS_1003172] | TMF
https://tmfaccess.mywingspan.com/wingspan-tmf/tmf/studyitemslist#detail/?state&id=1009551A000000000035EE5C&p=1&noCountries=false&noSi … 49/49Stati stical Anal ysis Plan -V2.0 -30-Jun-2020 
Electronic Signature [CONTACT_734122] a manifestation of the electronic signatu re(s) used in compliance with the organi zation's 
electronic signature [CONTACT_734123]. 
Si!mer Full Name [CONTACT_734124]2 of Si2nature Date and Time 
 Document Approval (I certify that I have the 29 Jun 2020 18:41:56 UTC 
education , training and experience to perform 
this task) 
 Document Approval (I certify that I have the 29 Jun 2020 21:10:52 UTC 
education , training and experience to perform 
this task) 
 Document Approval (I certify that I have the 29 Jun 2020 22:07 :59 UTC 
education , training and experience to perform 
this task) 
 Document Approval (I certify that I have the 30 Jun 2020 11: 14:30 UTC 
education , training and experience to perfo rm 
this task) 
Page [ADDRESS_1003173] 1000551A000000001 C2C 04F6 

 
Official Title:   
A Phase 1/2 open- label, multi -center, safety and tolerability study of a  
single dose of 68Ga -PSMA -R2 in patients with biochemical relapse (BR)  
and metastatic prostate cancer (mPCa)  
 
Study ID: [REMOVED]  
 
Document  Date :  
SAP Amendment 1 : [ADDRESS_1003174]  2018 
 
 
 
   
 
 
 
 
STATISTICAL ANALYSIS PLAN AMENDMENT 1 
PK AN
ALYSIS 
 
Advanced Accelerator Applications International SA Study Number:  A206D-A01-001 
Pr
otocol Version:  Version 2.2 
Pr
otocol Date: 22 February 2018 
 
 
 Phase Plan Number:  00144186  01129004 
 
 
A Phase 1/2 open-label, multi-center, safety and tolerability study of a single 
dose of 68Ga-PSMA-R2 in patients with biochemical relapse (BR) and 
metastatic prostate cancer (mPCa) 
 
SPONSOR: 
Advanced Accelerator Applications International SA 
4 rue de la Tour de l’île 
1204 Geneva, Switzerland 
TESTING FACILITY: 
 
 
 
[LOCATION_002] 
Page 1 of 11 

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 2  SUMMARY OF CHANGES AND JUSTIFICATIONS 
 
SAP effective date:    03 AUG 2018 
Note
:  When applicable, additions are indicated in bold underlined text and deletions are 
indicated in bold strikethrough text in the affected sections of the document. 
Item or Section(s)  Justification  
Amendment 1 Date: [ADDRESS_1003175]  2018  
Throughout Protocol  Update d  study number; the wrong study number was inadvertently 
used in the original protocol.  
5.[ADDRESS_1003176] responsible for the phase plan and sample 
analysis.  

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 3  TABLE OF CONTENTS 
SUMMARY OF CHANGES AND JUSTIFICATIONS .................................................................2 
1. INTRODUCTION ...................................................................................................................4 
2.
 OBJECTIVES ..........................................................................................................................4 
3.
 EXPERIMENTAL DESIGN ...................................................................................................4 
3.1.
 Overall Study Design and Plan ......................................................................................4 
3.2.
 Planned Pharmacokinetics Sampling Schedule .............................................................5 
4.
 GENERAL REPORTING SPECIFICATION: .......................................................................5 
4.1.
 Analyses to be Performed ..............................................................................................5 
4.2.
 Template and Guidelines to be Followed ......................................................................5 
4.3.
 Statistical Methods Planned ...........................................................................................5 
4.4.
 Software Description .....................................................................................................6 
5.
 EVALUATIONS: ....................................................................................................................6 
6.
 TABLES AND FIGURES .......................................................................................................9 
7.
 QUALITY ASSURANCE .....................................................................................................10 
8.
 REPORTS ..............................................................................................................................10 
9.
 AMENDMENT APPROVAL ...............................................................................................11 
 
 

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- [ADDRESS_1003177] ION 
This statistical analysis plan (SAP) describes the statistical methods to be used during the 
reporting of pharmacokinetic (PK) data collected under Advanced Accelerator Applications 
Inte
rnational SA (AAA) protocol Number:  A206D-A01-001.   
This SAP should be r
ead in conjunction with the study protocol and all applicable Statistical 
Analysis Plans and/or Workplans for the study. This version of the plan has been developed 
using the protocol document Version 2.2 dated 22 February 2018. Any further changes to the 
protocol m
ay require updates to the SAP.  Any deviation from this analysis plan will be 
desc
ribed in detail in the clinical report. An overall final report of pharmacokinetic data will be 
prepa
red and provided by .  
2.   OBJECTIVES 
The
 objectives of this study are as follows: 
Primary Objective: 
 To assess safety and tolerability of a single administration of 3 mega Becquerel 
(MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68Ga-PSMA- R2. 
 
Secondary Objective: 
 To assess the pharmacokinetics (PK), biodistribution, and dosimetry of 68Ga- PSMA-R2. 
 To establish the optimal imaging method for determining location and burden of positive 
lesions on 68Ga-
PSMA-R2 positron emission tomography (PET) imaging in patients in 
comparison with lesions identified with conventional imaging scans (computed tomography 
(CT)/magnetic resonance imaging (MRI) and bone scan), and to calculate the agreement of 
68Ga-PSMA-R2 PET with conventional anatomical/functional imaging on a per patient basis. 
3.   EXPERIMENTAL DESIGN 
3.1.   Overall Study Design and Plan  
This study is an open label, mu lti-center, single dose, safety and tolerability study of a diagnostic 
radio-pharmaceutical, in subjects with prostate cancer in biochemical relapse and metastatic 
prostate c
ancer (mPCa). During Phase 1, approximately [ADDRESS_1003178]-injection in order to 
assess the pha
rmacokinetics ( PK), biodistribution vs. time, and dosi metry for critical organs. 
Se
rial blood and urine samples will be collected for PK characterization. 
Two gro
ups of up to [ADDRESS_1003179] of 
subjects with prostate cancer in biochemical relapse (PC-BR), while the other will consist of 
pati
ents with prostate cancer in the metastatic stage (MPs). If preliminary data analysis from the 
Phase-[ADDRESS_1003180] 

 
Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- [ADDRESS_1003181]
ing will be omitted. 
Subjects enrolled in the dosimetry set of Phase 1, will enter the trial unit on the morning of the 
exam. Patients will receive a single dose of 3 MBq/kg, (≥ 150 and ≤ 250 MBq), of 68Ga-P SMA-
R2. The product will be prepared prior to administration and injected intravenously and each 
pati
ent will undergo a dosimetry study based on a series of PET/CT images.  
3.2.   Planned Pharmacokinetics Sampling Schedule  
 Whole blood samples (1 mL in heparinized tubes) will be collected from each of 6 
patients during Phase 1 immediately before administration of 68Ga-PSMA-R2 from the 
opposite arm of drug injection and then at the following approximate time-points 
following injection: 5 min, 10 min, 20 min, 40 min, 1 h, 2 h, 4 h, and 6 h 
 Total urine excreted from each of [ADDRESS_1003182]-injection: 0-20 min, 20 min – 1 h, 1 h – 2 h, 2 h -4 h and 4 h – 6 h. 
4.   GENERAL REPORTING SPECIFICATION:  
4.1.  
 Analyses to be Performed 
Listings, tables, and graphs that summarize 68Ga-PSMA-R2 whole blood concentrations and 
pharma
cokinetic parameters (as applicable) and 68Ga-PSMA-R2 urine recovery will be created 
by .  The data will be compi[INVESTIGATOR_69015] a final pharmacokinetic (PK) report.     
4.2.   Template and Guidelines to be Followed 
Reporting methods generally follow FDA guidelines for clinical data analysis and reporting. 
4.3.   Statistical Methods Planned 
No formal statistical analysis beyond descriptive statistics is planned.  Descriptive statistics will 
include number of observations (N), mean, standard error, geometric mean, %CV geometric 
mean (coefficient of variation of the geometric mean) calculation, median, min, and max for 
ea
ch parameter, where appropriate. 
Blood radioactivity data will be converted into mass concentration data (e.g. ng/mL), considering 
the specific radioactivity of the product and its radioactive decay.  Individual whole blood 
concentrations will be sorted by [CONTACT_734108]-specified sampling times.  Individual pharmacokinetic parameters will 
be li
sted by [CONTACT_734109].  Both individual and 
geometric mean profiles of whole blood concentrations of 68Ga-P SMA-R2 will be presented 
graphically using protocol-specified sampling times.  For all analyses, actual blood sampling 
times w
ill be used in the in the calculation of individual pharmacokinetic parameters.   

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 6  Missing data will not be imputed except for: 
 Tabulation of whole blood concentration data, where concentrations that are below the limit 
of quantification (BLQ) will be treated as zero. 
 Calculation of PK parameters, where BLQ concentrations will be treated as zero.  
 Embedded (i.e., BLQ concentrations bracketed by [CONTACT_734110], in a series of 
c
oncentration measurements constituting a reasonable profile) and/or terminal (after the last 
measureable concentration) BLQ concentrations will be treated as ’missing’.  
Unscheduled measurements will be listed in the individual data listings. Unscheduled 
measurements will be excluded from the descriptive statistical analysis. 
4.4.   Software Description 
The following software maintained at  will be used for the analysis: 
 Phoenix® WinNonlin® 6.4  for descriptive statistics calculations and non-compartmental analysis 
an
d generation of resulting tables.  Phoenix WinNonlin 6.4 has been fully validated in the 
operational environment at . 
 Gr
aphical presentations may be performed using Prism® for Windows, version 5.04. 
 Microsoft Excel spreadsheets may be utilized for reporting of interim summary results. 
 Final parameter results will be provided in Microsoft Excel spreadsheets and/or SAS transport 
files.  Specification documents will be provided as appropriate. 
5.   E VALUATIONS: 
5.1.   General Considerations (Controls, Data Rounding, etc.): 
Summary statistics will be presented with the same precision as the original data.  Percentages 
will be presented with one decimal place.  Concentrations reported as below the lower limit of 
quantitation (BLQ) will be set equal to zero for the purpose of analysis.  All data will be included 
in the analysis with the exceptions noted earlier, unless instructions are provided by [CONTACT_734111], e.g. problems during sampling 
or analysis or some other protocol deviation. 
5.2.   Non-compartmental Pharmacokinetic Endpoints and Method of Calculation: 
Data for individual subjects will be analyzed using non-compartmental methods. The whole 
blood PK parameters will be estimated from the whole blood concentration-time profiles for all 
subjec
ts included in the PK analysis set using Phoenix WinNonlin Version 6.[ADDRESS_1003183]
ing times will be used in the final analyses.  Protocol-specified times may be used for 
int
erim PHASE I analyses and actual times will be used for Final Analysis .  

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 7  In the pharmacokinetic parameter calculations, BLQ concentrations will be treated as zero except 
for e
mbedded (i.e., BLQ concentrations bracketed by [CONTACT_734110], in a series of 
conc
entration measurements constituting a reasonable profile) and/or terminal (after the last 
measureable concentration) which will be treated as “missing”. No attempt will be made to 
esti
mate missing PK data.  
The percentage of AUC 0-inf extrapolated (%AUCextra) AUCPEO  will be computed. For values 
larger than 20%, AUC 0-inf AUCIFO values will be flagged, but not excluded from the 
descriptive statistics. 
The elimination rate constant (kel LAMZ ) will be calculated by [CONTACT_734112]-transformed whole blood concentration. This terminal range will 
be de
termined by [CONTACT_734113] – time plots. C ma x CMAX will not be 
used for kel LAMZ determination. If adjusted R2 is lower than 0.80, the elimination rate 
constant and derived parameters will be flagged but not excluded from the descriptive statistics.  
For each PK parameter, summary statistics (including number of subjects, arithmetic mean, 
geometric mean (for T max TMAX no geometric mean will be calculated), SD, CV, median, Min 
and Max) will be presented. 
The following parameters for whole blood will be reported as data permits: 
CDISC coded variable names (PPTESTCD)  CDISC variable names ( PPTEST)  CDISC definition  
AUCLST  AUC to Last Nonzero Conc  The area under the curve 
(AUC) from the time of 
dosing to the last 
measurable concentration.  
AUCLSTD  AUC to Last Nonzero Conc 
Norm by [CONTACT_734114] 
(AUC) from the time of 
dosing to the last 
measurable concentration 
divided by [CONTACT_121287].  
AUCIFO  AUC Infinity Obs  The ar ea under the curve 
(AUC) extrapolated to 
infinity, calculated using 
the observed value of the 
last non -zero 
concentration.  
AUCPEO  AUC %Extrapolation Obs  The area under the curve 
(AUC) from the last 
observed non -zero 
concentration value to 
infinity as a pe rcentage of 
the area under the curve 
extrapolated to infinity.  
CMAX  Max Conc  The maximum 
concentration occurring at 
Tmax.  

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- [ADDRESS_1003184] non -zero 
concentration.  
LAMZHL  Half-Life Lambda z  Terminal half -life. 
MRTIVIFO  MRT Intravasc Infinity Obs  The mean residence time 
(MRT) extrapolated to 
infinity for a substance 
administered by 
[CONTACT_734115], 
calculated using the 
observed value of the last 
non-zero concentration.  
LAMZ  Lambda z  The first order rate 
constant associated with 
the terminal (log -linear) 
portion of the curve.  
 
 Cmax:  maximum whole blood concentration observed 
 Tmax:  Observed time of Cmax 
 AUC(0-t):  area under the concentration-time curve between the time of dose and the last 
measurable time point. 
 AUC(0-t)/D:  area under the concentration-time curve between the time of dose and the last 
measurable time point divided by [CONTACT_121287]. 

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 9   λz (Kel):  terminal elimination rate constant, determined by [CONTACT_149284]-linear whole blood concentration-time curve 
 T1/2:  elimination half-life, defined as 0.693/λz 
 AUCinf:  total AUC up to the last measurable concentration plus the AUC extrapolated from 
the last measurable concentration (C last at tlast) to infinity:  AUC(0-t) +C last/λz 
 %AUCextrap:  the percentage of AUC 0-inf that is extrapolated beyond the last measurable 
concentration: ( AUC 0-inf – AUC 0- t)/AUC 0-inf *100% 
 MRT: the mean residence time of 68Ga-PSMA- R2 
 CL:  clearance; calculated as 68Ga-PSMA- R2 Dose/ AUC 0-inf  
 Vd:  volume of distribution at steady-state; calculated as Mean Residence Time*CL 
 Vz : volume of distribution during the terminal phase  
 
Total recovery of 68Ga-PSMA-R2 in urine will be calculated as well as percent of dose excreted.  
Renal Cl RENAL CL of 68Ga-P SMA-R2 will be estimated as data permit. 
Additional parameters will be calculated automatically by [CONTACT_708465] 6.[ADDRESS_1003185]. 
5.3.   Compartmental Pharmacokinetic Endpoints and Method of Calculation: 
For compartmental analysis, an appropriate compartmental model (e.g. a 1 or 2 compartment 
model) wil
l be fit to the whole blood-concentration time profile using appropriate weighting. 
The final compartme
ntal model used to fit the data will be determined as the model that fits the 
data best.  Criteria used to assess the data fit criteria such as visual interrogation of predicted 
verses observed profiles, correlation coefficient closest to 1.00, and residual Y versus X plots 
that show re
sidual closest to 0 with no obvious positive or negative bias.  Comparisons of 
diffe
rent models and weighting schemes may also be evaluated using the Akaike Information 
criterion (AIC) with the model with the lowest AIC chosen as the best fit.  The parameters to be 
reporte
d based on the compartmental fit will be determined by [CONTACT_734116]. 
In the event that the data is not sufficient for fitting of a model, only parameters from the non-
compartmental analysis will be reported.   
6.   TABLES AND FIGURES 
 Ta ble 1:  Summary PK parameters (NCA) 
 Table 2:  Individual and Mean 68Ga-PSMA- R2 Whole Blood Concentration Versus Time 
 Table 3:  Individual PK Parameters (NCA) 
 Table 4:  Individual and Mean PK Parameters (Compartmental) 
 Table 4 5:  Individual PK Parameters (Compartmental) 

 
 Phase Plan No. : 00144186  01129004     AAA  Study No.:  A206D-A01- 001 
 Page 10  Table 56:  Individual and Mean Concentrations of 68Ga-P SMA- R2 in Urine and Urine 
Volumes 
 Table 6 7:  Individual and Mean Recovery of 68Ga-P SMA- R2 in Urine and Dose Recovered at 
Each Interval and Cumulative  
 Figure 1:  Individual 68Ga-PSMA-R2 Whole Blood Concentration Versus Time Profiles 
F
ollowing IP Injection (linear and semi-logarithmic scale) 
 Figure 2:  Geometric Mean 68Ga-PSMA-R2 Whole Blood Concentration Versus Time 
Profiles Following IP Injection (linear and semi-logarithmic scale) 
 Figure 3:  Individual and Geometric Mean C max CMAX Versus 68Ga- PSMA- R2 Dose 
 Figure 4:  Individual and Geometric Mean AUC (0-t) AUCLST Versus 68Ga-PSMA- R2 Dose 
 
Other Tables and Figures may be added at the discretion of the Sponsor and pharmacokineticist 
7.   QUALITY ASSURANCE 
The study will be audited by  [CONTACT_154505] (QA) in accordance with SOP 
QA-001 while in progress to assure compliance with applicable Good Laboratory Practice 
reg
ulations, adherence to the protocol and amendments, if any, and to  SOPs.   
8.   REPORTS 
The
re will be a final report generated for this study.  

9. AMENDMENT APPROVAL
Sponsor approval received via e-mail on 26 Sep 2018.
AJ^^^y O^OUTUl'Y
^r Thomas, PhD^ Date
haA ^{ _DM^US)^
 Maho ey, BS l ^ Date
ver Phase Plan No.: 00144186 01129004 AAA Study No.: A206D-AO 1-001
Page 11
